ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

Rindopepimut, Combination Immunotherapy Treatments Have Potential in Brain Cancer

David Reardon, MD
Published Online: 12:16 PM, Tue June 2, 2015


David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, and president, Society for Neuro-Oncology, discusses rindopepimut (CDX-110), a synthetic peptide vaccine, and its potential in brain cancer. Combination treatments that include checkpoint inhibitors and immunotherapy vaccines also show promise, says Reardon.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.